174 related articles for article (PubMed ID: 10469284)
41. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
Wimalawansa SJ
Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530
[TBL] [Abstract][Full Text] [Related]
42. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
Major PP; Coleman RE
Semin Oncol; 2001 Apr; 28(2 Suppl 6):17-24. PubMed ID: 11346861
[TBL] [Abstract][Full Text] [Related]
43. Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia.
Wüster C; Schöter KH; Thiébaud D; Manegold C; Krahl D; Clemens MR; Ghielmini M; Jaeger P; Scharla SH
Bone Miner; 1993 Aug; 22(2):77-85. PubMed ID: 8251767
[TBL] [Abstract][Full Text] [Related]
44. Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy.
Zysset E; Ammann P; Jenzer A; Gertz BJ; Portmann L; Rizzoli R; Jaquet-Müller F; Pryor-Tillotson S; Bonjour JP; Burckhardt P
Bone Miner; 1992 Sep; 18(3):237-49. PubMed ID: 1392697
[TBL] [Abstract][Full Text] [Related]
45. Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial.
Thürlimann B; Waldburger R; Senn HJ; Thiébaud D
Ann Oncol; 1992 Sep; 3(8):619-23. PubMed ID: 1450043
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.
Pecherstorfer M; Steinhauer EU; Rizzoli R; Wetterwald M; Bergström B
Support Care Cancer; 2003 Aug; 11(8):539-47. PubMed ID: 12783289
[TBL] [Abstract][Full Text] [Related]
47. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
Major P
Oncologist; 2002; 7(6):481-91. PubMed ID: 12490736
[TBL] [Abstract][Full Text] [Related]
48. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.
Major P; Lortholary A; Hon J; Abdi E; Mills G; Menssen HD; Yunus F; Bell R; Body J; Quebe-Fehling E; Seaman J
J Clin Oncol; 2001 Jan; 19(2):558-67. PubMed ID: 11208851
[TBL] [Abstract][Full Text] [Related]
49. Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients.
Pecherstorfer M; Schilling T; Blind E; Zimmer-Roth I; Baumgartner G; Ziegler R; Raue F
J Clin Endocrinol Metab; 1994 May; 78(5):1268-70. PubMed ID: 8175989
[TBL] [Abstract][Full Text] [Related]
50. [Tumor-induced hypercalcemia. Review of bisphosphonate treatment].
Lortholary A
Rev Med Interne; 2001 Jul; 22(7):648-52. PubMed ID: 11508158
[TBL] [Abstract][Full Text] [Related]
51. Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects?
Thürlimann B
Ann Oncol; 1994; 5 Suppl 7():S45-7. PubMed ID: 7532993
[TBL] [Abstract][Full Text] [Related]
52. Disodium pamidronate versus mithramycin in the management of tumour-associated hypercalcemia.
Ostenstad B; Andersen OK
Acta Oncol; 1992; 31(8):861-4. PubMed ID: 1290634
[TBL] [Abstract][Full Text] [Related]
53. Zoledronic acid.
Cheer SM; Noble S
Drugs; 2001; 61(6):799-805; discussion 806. PubMed ID: 11398911
[TBL] [Abstract][Full Text] [Related]
54. Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug.
Young RJ; Coleman RE
Future Oncol; 2013 May; 9(5):633-43. PubMed ID: 23647292
[TBL] [Abstract][Full Text] [Related]
55. Effect of a single infusion of alendronate in malignant hypercalcaemia: dose dependency and comparison with clodronate.
Rizzoli R; Buchs B; Bonjour JP
Int J Cancer; 1992 Mar; 50(5):706-12. PubMed ID: 1531972
[TBL] [Abstract][Full Text] [Related]
56. Tumor 'flare' hypercalcemia--an additional indication for bisphosphonates?
Nikolic-Tomasević Z; Jelic S; Popov I; Radosavljević D; Mitrović L
Oncology; 2001; 60(2):123-6. PubMed ID: 11244326
[TBL] [Abstract][Full Text] [Related]
57. Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia.
Mannix KA; Carmichael J; Harris AL; Cantwell BM
Cancer; 1989 Sep; 64(6):1358-61. PubMed ID: 2766228
[TBL] [Abstract][Full Text] [Related]
58. [Treatment of hypercalcaemic syndrome in tumour patients, especially with mithramycin].
Senn HJ; Peyer P
Dtsch Med Wochenschr; 1978 Jan; 103(3):101-7. PubMed ID: 146599
[TBL] [Abstract][Full Text] [Related]
59. [Clinical trial on ibandronate in patients with tumor-associated hypercalcemia].
Wang T; Song ST; Jiang ZF; Bian SG; Wang YJ; Li LQ; Zhu J
Zhonghua Zhong Liu Za Zhi; 2004 Dec; 26(12):739-41. PubMed ID: 15733393
[TBL] [Abstract][Full Text] [Related]
60. Dosing regimens and main adverse events of bisphosphonates.
Body JJ
Semin Oncol; 2001 Aug; 28(4 Suppl 11):49-53. PubMed ID: 11544576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
